AS
Assertio Holdings, Inc.
ASRT · NASDAQ
$23.50 +0.09% (+$0.02)
Market Cap $151.9M
P/E Ratio -
Div. Yield -
ROE 29.39%
Bulios Fair Price
$14.7
37.4% downside
Current Price
$23.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ASRT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
98 /100
Cheap P/S 1.28x
P/B 1.62x
P/E N/A
Growth
81 /100
Growing Rev. growth 12.06%
Book val. growth 35.47%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 70.19%
FCF margin 23.74%
Net margin 24.85%
Quality
6 /100
Poor ROIC 15.22%
Asset turnover 0.44x
ROE 29.39%
Debt
75 /100
Low Debt/Equity 0.42x
Net debt/EBITDA -7.79x
Current ratio 1.70x
Stability
35 /100
Moderate Beta 0.53x
Profitable years 0
Rev. volatility 23.66%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ASRT
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mark L. Reisenauer
Employees
58
Headquarters
Lake Forest